Alexion Pharma (ALXN) Tops Q3 EPS by 15c; Guides Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Reports Third Quarter 2015 Results
October 29, 2015 6:30 AM EDTSoliris® (eculizumab) Net Product Sales of $665.4 Million; Increased 20% Year-on-Year Despite 9% Currency Headwinds; 29% Volume Increase Year-on-Year -
- 2015 Non-GAAP EPS Guidance Increased to $4.92 to $4.97 -
Strensiq (asfotase alfa) Approved in the United States, European Union, Japan and Canada for Hypophosphatasia (HPP)
Kanuma (sebelipase alfa) Approved in the European Union for Lysosomal Acid Lipase Deficiency (LAL-D)
Completed Enrollment in Registration Trial of Eculizumab in Refractory MG and Progressed Registration Trials in Relapsing NMO and DGF
Advanced Complement and Metabolic Pipelines, Including ALXN 1210 and SBC-103
CHESHIRE, Conn.--(BUSINESS... More
